Tolerance and dose-response assessment of subchronic dietary ethoxyquin exposure in Atlantic salmon (Salmo salar L.)

PLoS One. 2019 Jan 25;14(1):e0211128. doi: 10.1371/journal.pone.0211128. eCollection 2019.

Abstract

Ethoxyquin (EQ; 6-Ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline) has been used as an antioxidant in feed components for pets, livestock and aquaculture. However, possible risks of EQ used in aquafeed for fish health have not yet been characterized. The present study investigated the toxicity and dose-response of subchronic dietary EQ exposure at doses ranging from 41 to 9666 mg EQ/kg feed in Atlantic salmon (Salmo salar L.). Feed at concentrations higher than 1173 mg EQ/kg were rejected by the fish, resulting in reduced feed intake and growth performance. No mortality was observed in fish exposed to any of the doses. A multi-omic screening of metabolome and proteome in salmon liver indicated an effect of dietary EQ on bioenergetics pathways and hepatic redox homeostasis in fish fed concentrations above 119 mg EQ/kg feed. Increased energy expenditure associated with an upregulation of hepatic fatty acid β-oxidation and induction and carbohydrate catabolic pathways resulted in a dose-dependent depletion of intracytoplasmic lipid vacuoles in liver histological sections, decreasing whole body lipid levels and altered purine/pyrimidine metabolism. Increased GSH and TBARS in the liver indicated a state of oxidative stress, which was associated with activation of the NRF2-mediated oxidative stress response and glutathione-mediated detoxification processes. However, no oxidative DNA damage was observed. As manifestation of altered energy metabolism, the depletion of liver intracytoplasmic lipid vacuoles was considered the critical endpoint for benchmark dose assessment, and a BMDL10 of 243 mg EQ/kg feed was derived as a safe upper limit of EQ exposure in Atlantic salmon.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animal Feed
  • Animals
  • DNA Damage
  • Dose-Response Relationship, Drug
  • Eating / drug effects*
  • Energy Metabolism / drug effects*
  • Ethoxyquin / pharmacology*
  • Lipid Metabolism / drug effects*
  • Liver / metabolism*
  • Salmo salar / metabolism*

Substances

  • Ethoxyquin

Grants and funding

This study was financed by the Norwegian Seafood Research Fund (FHF; https://www.fhf.no/), the Marine Ingredients Organisation (IFFO) Marine Harvest ASA, EWOS AS/Cargill Aqua Nutrition, Biomar AS, Skretting AS and Europharma (FHF project no. 901327). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.